Literature DB >> 23948549

Up-regulation of pro-angiogenic factors and establishment of tolerance in malignant pleural effusions.

Elizabeth Ann T Lieser1, Gary A Croghan, Wendy K Nevala, Michael J Bradshaw, Svetomir N Markovic, Aaron S Mansfield.   

Abstract

INTRODUCTION: Malignant pleural effusions (MPEs) are a significant source of cancer morbidity and mortality. Currently there is no cure for MPEs and treatments only palliate the symptoms. The purpose of this study was to determine if there are differences in markers of angiogenesis and immune phenotypes between adenocarcinoma-induced MPEs and benign pleural effusions (BPEs).
METHODS: Pleural effusions were collected from patients with MPEs and BPEs. Cells were isolated from effusions and characterized using fluorescent cell sorting (FACS). Pleural effusions were evaluated by ELISA for VEGF-A. An angiogenesis protein array was completed to compare protein expression in malignant and non-malignant effusions.
RESULTS: FACS analysis demonstrated lower accumulation of cytotoxic T-cells and significantly higher accumulation of monocytes, dendritic cells, mesothelial and tumor cells in MPEs compared to benign pleural effusions. MPEs were found to have 77-fold higher VEGF-A levels compared to BPEs. The angiogenesis protein array demonstrated elevated levels of pro-angiogenic factors VEGF-A, CXCL4 and MMP-8, and low levels of pro-inflammatory cytokines IL-8, MCP-1, and TGF-β1 in MPEs.
CONCLUSIONS: MPE is biased toward a Th2 dominant state. There is an increase in expression of VEGF-A and other pro-angiogenic factors in MPE. These data suggest there is a role for anti-angiogenesis therapy in patients with MPEs.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Angiogenesis; Benign pleural effusion; Chronic inflammation; Immunity; Malignant pleural effusion; Vascular endothelial growth factor (VEGF)

Mesh:

Substances:

Year:  2013        PMID: 23948549     DOI: 10.1016/j.lungcan.2013.07.007

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  10 in total

Review 1.  Making cold malignant pleural effusions hot: driving novel immunotherapies.

Authors:  Pranav Murthy; Chigozirim N Ekeke; Kira L Russell; Samuel C Butler; Yue Wang; James D Luketich; Adam C Soloff; Rajeev Dhupar; Michael T Lotze
Journal:  Oncoimmunology       Date:  2019-01-22       Impact factor: 8.110

Review 2.  Closing faucets: the role of anti-angiogenic therapies in malignant pleural diseases.

Authors:  D Marquez-Medina; S Popat
Journal:  Clin Transl Oncol       Date:  2015-12-17       Impact factor: 3.405

3.  Intrapleural Administration With Rh-Endostatin and Chemical Irritants in the Control of Malignant Pleural Effusion: A Systematic Review and Meta-Analysis.

Authors:  Cheng-Qiong Wang; Xiao-Rong Huang; Min He; Xiao-Tian Zheng; Hong Jiang; Qian Chen; Teng-Yan Fan; Lin Zhan; Juan Ling; Ji-Hong Feng; Xue Xiao; Xiao-Fan Chen; Zheng Xiao
Journal:  Front Oncol       Date:  2021-08-03       Impact factor: 6.244

4.  Small cell lung cancer: Recruitment of macrophages by circulating tumor cells.

Authors:  Gerhard Hamilton; Barbara Rath; Lukas Klameth; Maximilan J Hochmair
Journal:  Oncoimmunology       Date:  2015-10-29       Impact factor: 8.110

Review 5.  Malignant Pleural Effusions-A Window Into Local Anti-Tumor T Cell Immunity?

Authors:  Nicola Principe; Joel Kidman; Richard A Lake; Willem Joost Lesterhuis; Anna K Nowak; Alison M McDonnell; Jonathan Chee
Journal:  Front Oncol       Date:  2021-04-27       Impact factor: 6.244

Review 6.  Systematic review and meta-analysis of vascular endothelial growth factor as a biomarker for malignant pleural effusions.

Authors:  Eleftheria Fafliora; Chrissi Hatzoglou; Konstantinos I Gourgoulianis; Sotirios G Zarogiannis
Journal:  Physiol Rep       Date:  2016-12

7.  Non-significant efficacy of icotinib plus pleurodesis in epidermal growth factor receptor positive mutant lung cancer patients after malignant pleural effusion drainage compared to icotinib alone.

Authors:  Yunhua Xu; Wangsheng Fang; Bingye Cheng; Shanshan Chen; Linping Gu; Li Zhu; Yan Pan; Zhen Zhou
Journal:  J Thorac Dis       Date:  2020-05       Impact factor: 2.895

8.  A meta-analysis of Th1 and Th2 cytokine profiles differentiating tuberculous from malignant pleural effusion.

Authors:  Yulin Zeng; Liwei Wang; Hai Zhou; Yu Qi
Journal:  Sci Rep       Date:  2022-02-17       Impact factor: 4.379

9.  The Meta-Analysis of Bevacizumab Combined with Platinum-Based Treatment of Malignant Pleural Effusions by Thoracic Perfusion.

Authors:  Bairu Shen; Minghua Tan; Zhengyu Wang; Changshan Song; Hui Hu; Shunfu Deng; Yuxin Yang
Journal:  J Oncol       Date:  2022-02-25       Impact factor: 4.375

10.  Monocytes subtypes from pleural effusion reveal biomarker candidates for the diagnosis of tuberculosis and malignancy.

Authors:  Lisha Luo; Shuanglinzi Deng; Wei Tang; Xinyue Hu; Feifei Yin; Huan Ge; Jiale Tang; Zhonghua Liao; Juntao Feng; Xiaozhao Li; Biwen Mo
Journal:  J Clin Lab Anal       Date:  2022-07-12       Impact factor: 3.124

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.